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To Treat or Not To Treat—From Guidelines to
Individualized Patient Management
Axel Matzdorff,a Ellis J. Neufeld,b and Jelena RoganoviccImmune thrombocytopenia (ITP) is a rare disorder. Evidence-based guidelines provide0037-1963
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S12important information for hematologists, as well as diagnostic and therapeutic recommenda-
tions to other physicians with limited expertise in the field. However, guidelines in pediatric
and adult ITP do not answer some imperative questions: which patient is at risk of severe
bleeding and requires pharmacologic treatment? Who will recover spontaneously? Is splenec-
tomy still an appropriate second-line treatment for all chronic or persistent ITP patients? This
review summarizes the current approach to these important issues, the patients’ perspective,
and how we can improve individual patient management.
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mmune thrombocytopenia (ITP) is rare with an
incidence ranging from 1.6-3.9 per 100,000
persons per year.1 The average pediatrician or
internal medicine doctor will see only a handful of
cases during the professional lifetime. Therefore,
personal experience with ITP care is often limited.
To address the need for more information and
recommendations, the American Society of Hematol-
ogy (ASH) established an expert panel in 1994 and
eventually published the 1996 ASH practice guide-
line.2 Although since that time there have been
important publications on standardizing the termi-
nology and definitions of ITP, as well as on the
investigation and the treatment of the disease, this
guideline is still one of the most cited articles in
the field.
The need for more information was not limited to
physicians. In 1995 the ITP Support Association was
founded in the United Kingdom by Shirley Watson
whose son had ITP. The Platelet Disorder Support
Association (PDSA) started in the United States inblished by Elsevier Inc.
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tion among patients. In 2003 the first patient repre-
sentative coauthored the British ITP guideline.3
Patient-reported outcomes (PROs) started to provide
information from the patient’s perspective. Health-
related quality of life (HRQoL) measures as the most
commonly assessed PRO in clinical research thus
became very useful components for evaluating and
understanding the effects of disease and medications
from the patients’ perspective.
The advent of rituximab at the end of the 1990s
and thrombopoietin receptor agonists in the last
decade generated interest in the clinical community
and changed the situation. The high costs of these
drugs threatened to limit financial resources either of
the individual patient or the public health care
systems. At the same time, introduction of new
drugs prompted activities to revise existing recom-
mendations. During the last years several updates
have been published, the most relevant being the
international consensus report on the investigation
and management of primary ITP in 20104 and the
new ASH 2011 evidence-based practice guideline for
ITP.5 Many patients feel that these publications
primarily address clinicians’ needs and do not reflect
the impact of the disease and treatments on their
daily life. This is perceived as a growing gap between
academic medicine and treatment reality. There is an
unmet need for a more individualized patient
approach. Which patient is really at risk of severe
bleeding and requires pharmacologic treatment?
Who will recover spontaneously and could be
treated with observation alone? Is splenectomy still
a proper second-line treatment for all chronic
patients unresponsive to initial measures?ology, Vol 50, No 1, Suppl 1, January 2013, pp S12–S17
Table 1. Eight Countries With Experts Present
at the Subgroup Meeting on Individualized
Management Approaches in ITP
 Argentina
 Croatia
 Germany
 Israel
 Italy
 Netherlands
 Patient Support Group (PDSA–US)
 United States (Brooklyn, Boston, Augusta,
Dallas)
To treat or not to treat S13In September 2012 a group of ITP specialists from
nearly 20 different countries came together at the
4th International Cooperative ITP Study Group
(ICIS) Expert Meeting in Montreux, Switzerland. A
subgroup representing eight countries discussed
‘‘individualized patient care’’ (Table 1). The group
discussed different subjects from basic science to
daily care, relating to the questions posed above, as
well as variations in treatment practice from center
to center (Table 2). This article provides a summary
from the symposium on individualized patient
management.Table 2. Subjects Discussed at the Subgroup Meetin
Given the available data and published guidelines:
– What do we actually do for our patients?
– What should we do?
– What do our patients want?
Initial management:
– Corticosteroids for all?
– What considerations should be taken into account in
Strategies when the initial management is not working
– Which second-line agent?
– Is ’’observation only’’ an option?
What should a next round of guidelines address?
– What necessary studies remain undone?
– What shortcomings arise in strict adherence to evide
– When there are no data on certain clinical problems
recommendations or are opinional statements app
– What is the future role of patient support groups in
– What is the future role of physicians: stewards of the
What are the best ways forward?
– Collaborations/consortia working in parallel
– Will standardized clinical assessment and managemeTHERE ARE MORE THINGS IN HEAVEN AND
EARTH THAN CAN BE DREAMT
OF—SPONTANEOUS RECOVERY IN ITP
A newly diagnosed ITP patient with significant
bleeding is a clear indication for first-line treatment.
But what about the patient with a very low platelet
count and absent or only minor bleeding? One third
of adult ITP patients are completely asymptomatic
and diagnosed by chance during a work-up for other
medical problems.6 Only 3% of children with ITP
have clinically significant manifestations such as
severe epistaxis or gastrointestinal bleeding.7 Can
one wait for spontaneous remission in asymptomatic
or oligosymptomatic patient?
The first-line treatment has never been shown to
avert the development of chronic ITP or reduce
morbidity during follow-up. Nevertheless, to date
most newly diagnosed ITP patients receive treat-
ment with corticosteroids or intravenous immuno-
globulins (IVIg) irrespective of severity of
hemorrhage and only because their platelet counts
are low. The approaches to an asymptomatic or
oligosymptomatic child and adult vary from country
to country, among institutions within a country, and
sometimes even among experts in one institution.
Moreover, the same clinician can make different
decisions depending on the day of the week, with
a higher likelihood to treat a patient on weekends
when experienced senior physicians are not ‘‘rightg
deciding upon initial therapy?
:
nce-based guidelines?
, should guidelines refrain from giving
ropriate?
guideline writing?
ir patients or of healthcare resources?
nt plans (SCAMPs) prove to be a helpful tool?
A. Matzdorff, E.J. Neufeld, and J. RoganovicS14next door.’’ Fear of litigation may also influence
these decisions in some healthcare systems. Children
with ITP have an excellent prognosis, with 80% of
patients recovering completely within 6 months.
The remission in pediatric ITP correlates with sud-
den onset of disease and younger age, and is not
correlated with the treatment.8 Spontaneous remis-
sions in adults with ITP do occur too, although they
are much less common compared with children. The
true remission rate is not known, because most adult
patients are promptly treated with glucocorticoids.
There is evidence that a great proportion of ITP
adults achieve remission even without splenectomy,
30% of them within the first 6 months increasing up
to 53% three years after diagnosis.9 The 2011 ASH
guideline recommends longer courses of cortico-
steroids over shorter courses or IVIg as first-line
treatment based on the results of one study.5,10
Considering adverse effects of long-term corticoste-
roids, it would be extremely helpful to have some
easily accessible criteria to identify patients who will
recover spontaneously and spare them unnecessary
toxicities.COME, YOU SPIRITS! MAKE THICK MY
BLOOD!—WHICH PATIENT IS AT RISK OF
BLEEDING?
The primary anxiety of all ITP patients, parents,
and treaters, is severe bleeding, with intracranial
hemorrhage being the most feared complication.
Platelet count is widely used as a surrogate marker
for bleeding risk because the risk for severe bleeding
increases when the platelet count drops below
10,000/mL.11 Several bleeding scores have been
designed for objective quantification of bleeding
symptoms, mostly for pediatric patients.12-15 They
were never commonly integrated in clinical practice
for various reasons, including complexity and time
required for completion. Risk factors for intracere-
bral bleeding in children with severe ITP include
head trauma and concomitant use of medications
that adversely affect platelet function. It still remains
questionable whether the severity of mucocutane-
ous bleeding really predicts the risk for life-
threatening bleeding. In adults, intracranial hemor-
rhage may be a more common complication of ITP
than previously appreciated, with the cumulative
incidence being 2.67% in recent large cohort
study.16 Increasing age, low platelet count, and
certain medical co-morbidities but not mucocutane-
ous bleeding could be correlated with severe
bleeds.17,18
The 1996 ASH guideline panel considered it
inappropriate to withhold treatment even at the
patient’s request if the platelet count waso20,000/
mL. This was a fairly strong statement considering theabsence of any evidence. Not a few patients ended
up with high-dose corticosteroids for very long time
according to this recommendation. The 2009 Interna-
tional Consensus Statement4 acknowledged this,
conceding that it would be acceptable to live with
low platelet counts foregoing further toxic treat-
ments as long as patients have no or only very mild
bleeding and near normal quality of life. Then the
2011 ASH guideline authors had only minor changes
from 1996, reintroducing the platelet count in treat-
ment decisions, because the ’’majority of clinicians
use threshold ofo30,000 as a trigger for treatment,
and they find no evidence to contradict this prac-
tice.’’5 Can we do better? There is an urgent need to
identify patients at risk of severe bleeding and spare
all others corticosteroid-related toxicities.19TRUE APOTHECARY. THY DRUGS ARE
QUICK.—TOO MUCH STEROIDS FOR TOO
LONG TIME
William Osler wrote: the desire to take medicine
is perhaps the greatest feature which distinguishes
man from animals. Osler may have been wrong. ITP
patients do not like their medications and particu-
larly dislike corticosteroids. Despite this aversion,
between 90% and 100% of adult patients have
received or receive corticosteroids during the course
of their disease, many for prolonged periods.20–22
The 2011 ASH guideline supports prolonged use of
corticosteroids as first-line treatment over shorter
courses. Treatment guidelines discuss side effects
but put much emphasis on hypertension, hyper-
glycemia, cataracts, and osteoporosis. Instead, the
side effects most bothersome to patients receiving
prednisone and dexamethasone are weight gain,
increased appetite, changes in personality, mood or
emotions, ’’moon face’’ or puffy cheeks, bloating,
swelling, and sleep disturbances. Children often
experience hyperactivity. Patients rank treatment-
bother with corticosteroids higher than with any
other ITP therapy.23,24 There is no treatment for
moon face. It is not surprising that in one survey
many patients stated that they had feeling their
doctors did not know enough about ITP and its
impact on their quality of life.25 In another study,
59% of patients responded that they felt their
physicians often paid an appropriate amount of
attention to their corticosteroid side effects. How-
ever, the differences between patients’ and hema-
tologists’ perception of the number and severity of
corticosteroid side effects experienced by ITP
patients suggest that communication may be
improved.26 Almost 50% of patients are not satisfied
with traditional therapy and turn to complementary
and alternative medicines (CAMs).19,22
To treat or not to treat S15THE PEACE IS THEIRS THAT LIFT THEIR
SWORDS!—SPLENECTOMY
The first report of a successful therapy for ITP was
in 1916, when a young Polish medical student, Paul
Kaznelson, described a female patient responding to
splenectomy. Splenectomy remained up-front treat-
ment until the introduction of corticosteroids in the
1950s. It was the standard second-line treatment in
the 1996 ASH guideline and in 2011 still receives a
strong recommendation for patients who have failed
initial therapy. But in contrast to expert recommen-
dations, most patients do not undergo splenectomy.
Most of them who accept it perceive their disease as
having a negative impact on their quality of life,
whereas patients who refuse it feel their situation is
not severe enough to warrant surgery. Studies on
new thrombopoetin receptor agonists in chronic ITP
show that to date only about 30% of patients had
undergone splenectomy. Considering a sustained
response rate of approximately 70% with splenec-
tomy, physicians might perceive patients’ fear as
irrational. What it really reflects is that all ITP
patients have been told from the first day to avoid
activities where injuries are likely if they don’t want
to ‘‘bleed to death.’’ It is therefore coherent that
they try to avoid any invasive procedure, including
splenectomy. With the availability of new effective
agents and in the light of the one-third long-term
failure rate of splenectomy, the desire to postpone
or even avoid it becomes understandable. We
urgently need guidance on which patients have a
clear indication for splenectomy and which not.27ET TU, BRUTE?—THE CHARACTER OF
MEDICINE HAS CHANGED
With the advent of rituximab and thrombopoietin
receptor agonists, many chronic ITP patients voiced
the legitimate desire to use these new agents before
splenectomy. In the absence of randomized studies
this was supported by opinioned statements of many
experts in the field.28-31 However, it did not affect
licensure status. Rituximab is still off-label. Sustained
remission rates with rituximab are disappointing.
Thrombopoietin receptor agonists are restricted to
adult patients at risk of bleeding who relapse after
splenectomy or have a contraindication to splenec-
tomy and have failed another therapy. The high
response rates have been reported in randomized
trials of refractory post-splenectomy patients treated
with thrombopoetin mimetics. How could we pro-
vide clinical data for a more logical treatment
algorithm? The persistent support for splenectomy
as second-line treatment in the International Con-
sensus Statement and the 2011 ASH guideline has
the smack that cost may have influenced thisdecision. Splenectomy is much cheaper than throm-
bopoetin receptor agonists. The authors of the
International Consensus Report openly admitted that
their recommendations were influenced by cost
considerations.4 Although high costs of modern
drugs could limit their availability, it seems like
physicians have accepted their role as stewards of
the healthcare system. It is not surprising that self-
support groups have become very attractive for ITP
patients.THE HEART OF HEARTS—WHAT NEEDS TO BE
ADDRESSED IN FUTURE GUIDELINES
The foundation of self support groups in the
1990s in the United Kingdom and the United States,
and thereafter in many other countries, reflects the
growing gap between academic medicine and treat-
ment reality. Many patients turn to CAMs outside the
system of traditional and school medicine. Surveys
show that almost half of the patients try CAMs at
some time during their course of disease.20–22
Besides bleeding risk, splenectomy and limited
access to new agents, there are more problems
confronted by our patients: fatigue; effect of the
disease on occupation, lifestyle activities, and fami-
lies; and health insurance problems. None of these
has been addressed in the current guidelines. The
absence of data should not justify the absence of
expert opinion. It is a legitimate request of our
patients to get answers to these pressing ques-
tions.32 Each expert has his personal approach to
these problems. Larger institutions have an oppor-
tunity to combine their experience using SCAMPs,
which are flexible, outcomes-based practice guide-
lines that allow for variation from written manage-
ment strategies, but clinicians must explain their
reasons for variation, and iteratively the management
plans can be changed.33
ITP has a very long history. The first reports date
back to the 16th and 17th centuries. It was German
physician and poet Paul Gottlieb Werlhof who wrote
in 1735 the most complete initial report of purpura
of ITP.34 More than 50 years ago Jeanne Lusher, the
doyenne of pediatric ITP, wrote that we should treat
the patient, not the platelet count.35 Has anybody
listened? We still treat patients who may not need
treatment with medications they dislike to achieve
goals that do not mean very much. A wide variety of
controversial studies and review articles are being
published. We can do better. The following articles
on splenectomy,27 bleeding risk,19 and spontaneous
recovery36 will highlight current knowledge and
how we can improve. If in 10 years a new expert
panel convenes again to provide consensus-based
recommendations on ITP, then it should address the
A. Matzdorff, E.J. Neufeld, and J. RoganovicS16perspectives of all involved in the field, including
physicians, the healthcare system, and patients.REFERENCES
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